These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33460545)

  • 1. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
    Tsapas A; Karagiannis T; Avgerinos I; Matthews DR; Bekiari E
    Ann Intern Med; 2021 Jan; 174(1):141. PubMed ID: 33460545
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
    Kabadi UM
    Ann Intern Med; 2021 Jan; 174(1):140. PubMed ID: 33460546
    [No Abstract]   [Full Text] [Related]  

  • 3. In type 2 diabetes, some glucose-lowering drugs reduce HbA
    Gandhi GY
    Ann Intern Med; 2020 Nov; 173(10):JC53. PubMed ID: 33197350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
    Schernthaner G
    Lancet Diabetes Endocrinol; 2021 May; 9(5):251-252. PubMed ID: 33798462
    [No Abstract]   [Full Text] [Related]  

  • 5. Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta-analysis: GLUCOSE DINET protocol-Rational and design.
    Grenet G; Lajoinie A; Ribault S; Nguyen GB; Linet T; Metge A; Cornu C; Cucherat M; Moulin P; Gueyffier F
    Fundam Clin Pharmacol; 2017 Jun; 31(3):258-264. PubMed ID: 28036112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of Non-Insulin Glucose Lowering Drugs.
    Kalra S; Arora S; Kapoor N
    J Pak Med Assoc; 2022 Jan; 72(1):181-182. PubMed ID: 35099465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative Management of Glucose-lowering Drugs: Comment.
    Gregory SH
    Anesthesiology; 2021 Feb; 134(2):349. PubMed ID: 33433618
    [No Abstract]   [Full Text] [Related]  

  • 9. Perioperative Management of Glucose-lowering Drugs: Comment.
    Thiruvenkatarajan V; Jesudason D; Nanjappa N; Meyer EJ; Van Wijk RM
    Anesthesiology; 2021 Feb; 134(2):349-350. PubMed ID: 33433615
    [No Abstract]   [Full Text] [Related]  

  • 10. Perioperative Management of Glucose-lowering Drugs: Reply.
    Preiser JC; Cnop M
    Anesthesiology; 2021 Feb; 134(2):350-351. PubMed ID: 33433614
    [No Abstract]   [Full Text] [Related]  

  • 11. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?
    Lee CG; Cefalu WT
    Ann Intern Med; 2020 Aug; 173(4):311-312. PubMed ID: 32598225
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
    Lan J; Zhao Y; Dong F; Yan Z; Zheng W; Fan J; Sun G
    J Ethnopharmacol; 2015 Feb; 161():69-81. PubMed ID: 25498346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forever Starts Now: Effects of Glucose-Lowering Therapies on Acute Kidney Injury.
    Kotwal S; Perkovic V
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):6-8. PubMed ID: 33376104
    [No Abstract]   [Full Text] [Related]  

  • 18. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis.
    Campbell IW; Howlett HC
    Diabetes Metab Rev; 1995 Sep; 11 Suppl 1():S57-62. PubMed ID: 8529486
    [No Abstract]   [Full Text] [Related]  

  • 19. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA
    Tanner M
    Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients.
    Taylor SI
    Diabetes Care; 2020 Oct; 43(10):2330-2332. PubMed ID: 32958616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.